COVID-19 Clearance with Favipiravir - A Retrospective Study
Favipiravir in COVID-19
Abstract
Background: Pharmacotherapy of Severe Acute Respiratory Corona Virus-2 (SARS-CoV-2), also denoted as COVID-19 is evolving. Many antivirals were found to be ineffective. Antiviral therapy used in 2020 was not originally developed for COVID-19. The effectiveness of favipiravir (an original drug for influenza) in COVID-19 pneumonia is questionable.
Methods: A small sample retrospective study was conducted to indicate if favipiravir is effective in COVID-19 clearance. It was conducted in a tertiary-level care hospital in the United Arab Emirates. COVID-19 pneumonia patients were admitted to the hospital from January to December 2020 were studied. SPSS version 26 was used for the data analysis.
Results: The average day of COVID-19 clearance for those who received favipiravir alone or favipiravir and hydroxychloroquine together were 12 days. Those who received no antivirals had COVID-19 clearance in an average of 11 days. Independent-Samples Kruskal-Wallis Test shows no statistically significant difference (p-value 0.663) in the length of COVID-19 clearance between these three treatment groups.
Conclusion: Favipiravir was not effective in mild COVID-19 pneumonia for achieving COVID-19 clearance. The effectiveness of favipiravir on COVID-19 clearance needs to be studied further.
How to cite this article:
Alshamsi RK, Thomas D, Hussein S. COVID-19 Clearance with Favipiravir - A Retrospective Study. Special Issue - COVID-19 & Other Communicable Disease. 2022;258-262.
DOI: https://doi.org/10.24321/0019.5138.202239
References
Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Jun;46(6):1099-102. [PubMed] [Google Scholar]
Simonis A, Theobald SJ, Fätkenheuer G, Rybniker J, Malin JJ. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Mol Med. 2020 Jan;13(1):e13105. [PubMed] [Google Scholar]
National committee for Management of COVID-19 Cases
[Internet]. National Guidelines for Clinical Management and Treatment of COVID-19 April 3rd, 2020. Ministry of Health and Prevention, Dubai Health Authority, Department of Health; 2020 [cited 2021 Jan 21]. Available from: https://www.dha.gov.ae/en/HealthRegulation/Documents/COVID%20National%20Guidelines%20FINAL%2018%20March.pdf
Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother. 2020 Jul;75(7):2013-4. [PubMed] [Google Scholar]
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov;383(19):1813-26. [PubMed]
WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández GarcÃa C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, GarcÃa PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed antiviral drugs for COVID-19 - interim WHO SOLIDARITY trial results. N Engl J Med. 2021 Feb;384(6):497-511. [PubMed] [Google Scholar]
Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, Zhang HY, Sun W, Wang Y. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-83. [PubMed] [Google Scholar]
Agrawal H, Das N, Nathani S, Saha S, Saini S, Kakar SS, Roy P. An assessment on impact of COVID-19 infection in a gender-specific manner. Cancer Biol Ther. 2020 Feb;17(1):94-112. [PubMed] [Google Scholar]
Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Ther. 2020 Aug;17(3):519-27. [PubMed] [Google Scholar]
Barek MA, Aziz MA, Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: a meta-analysis with 55 studies and 10014 cases. Heliyon. 2020 Dec;6(12):e05684. [PubMed] [Google Scholar]
van Paassen J, Vos JS, Hoekstra EM, Neumann KM, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24(1):e7966. [PubMed] [Google Scholar]
Chen X, Zhu B, Hong W, Zeng J, He X, Chen J, Zheng H, Qiu S, Deng Y, Chan JC, Wang J, Zhang Y. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. Int J Infect Dis. 2020 Sep;98:252-60. [PubMed] [Google Scholar]
Elavarasi A, Prasad M, Seth T, Sahoo RK, Madan K, Nischal N, Soneja M, Sharma A, Maulik SK, Garg P. Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis. J Gen Intern Med. 2020 Nov;35(11):3308-14. [PubMed] [Google Scholar]
Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Update alert: hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19. Ann Intern Med. 2020 Aug;173(4):287-96. [PubMed] [Google Scholar]
Shakoor H, Feehan J, Al Dhaheri AS, Ali HI, Platat C, Ismail LC, Apostolopoulos V, Stojanovska L. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: could they help against COVID-19? Maturitas. 2021 Jan;143:1-9. [PubMed] [Google Scholar]
Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, Skanderson M, Brittain E, King JT Jr, Ho YL, Eden S, Kundu S, Lann MF, Greevy RA Jr, Ho PM, Heidenreich PA, Jacobson DA, Douglas IJ, Tate JP, Evans SJW, Atkins D, Justice AC, Freiberg MS. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021 Feb;372:n311. [PubMed] [Google Scholar]
Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021 Jan;102:501-8. [PubMed] [Google Scholar]
Martinez MA. Clinical trials of repurposed antivirals for SARS-CoV-2. Antimicrob Agents Chemother. 2020 Aug;64(9):e01101-20. [PubMed] [Google Scholar]
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C, Li X, Peng L, Huang D, Zhang J, Zhang S, Wang F, Liu J, Chen L, Chen S, Wang Z, Zhang Z, Cao R, Zhong W, Liu Y, Liu L. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020 Oct;6(10):1192-8. [PubMed] [Google Scholar]
Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, Gordeev IG, Ilin AP, Karapetian RN, Kravchenko DV, Lomakin NV, Merkulova EA, Papazova NA, Pavlikova EP, Savchuk NP, Simakina EN, Sitdekov TA, Smolyarchuk EA, Tikhomolova EG, Yakubova EV, Ivachtchenko AV. AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2020 Aug;73(3):531-4. [PubMed] [Google Scholar]
Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y, Kondo M. A prospective, randomized, open-label trial of early versus late Favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020 Nov;64(12):e01897-20. [PubMed] [Google Scholar]
Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, Chen G, Wang K, Yu J, Wu Z, Chen X, Wang G. Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size. Biomed Pharmacother. 2021 Jan;133:110825. [PubMed] [Google Scholar]
Copyright (c) 2022 Author's
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
